摘要
帕金森病(Parkinson disease,PD)是中老年常见的神经系统变性疾病,其发病率和患病率随着年龄的增长而上升。临床上传统药物治疗并不能改变疾病的进展,因此迫切需要找到治疗PD的新靶点。越来越多的研究表明胰高血糖素样肽1(Glucagon-like peptide-1,GLP-1)对PD具有神经保护作用。本文对GLP-1和GLP-1R分布及相关生理作用、GLP-1神经保护作用分子机制的研究进展进行综述,发现GLP-1能通过减少α-突触核蛋白聚集、抗炎、抗氧化等多种生物学机制发挥对PD的神经保护作用,从而达到改善运动障碍及延缓认知障碍的治疗效果,这些发现将为PD的治疗带来新的思路,同时为今后开展相关研究提供依据。
Parkinson's disease(PD)is a common neurological degenerative disease in middle-aged and elderly people,and its incidence and prevalence increase with age.The traditional drugs used to treat PD cannot change the progression of the disease.Therefore,it is urgent to find new targets to treat the disease.More and more studies have shown that Glucagon-like peptide 1(GLP-1)has a neuroprotective effect on PD.This article reviews the distribution and related physiological effects of GLP-1 and GLP-1R,as well as the molecular mechanism of the neuroprotective effect of GLP-1.It is found that GLP-1 can play a neuroprotective role in PD by reducingα-synuclein aggregation,anti-inflammatory,antioxidant and other biological mechanisms,so as to improve the therapeutic effect of movement disorders and delay cognitive impairment.These findings will bring new ideas for the treatment of PD,and provide a basis for future related research.
作者
周丽琴
王婕妤
刘南海
ZHOU Li-qin;WANG Jie-yu;LIU Nan-hai(The First Clinical Medical School of Gannan Medical University;The First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi 341000)
出处
《赣南医学院学报》
2023年第12期1219-1223,共5页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
